Recursion Pharmaceuticals Inc
RXRX5.030USD
-0.370-6.85%
Close 06/27, 16:00（ET）Quotes delayed by 15 min
2.04BMarket Cap
LossP/E TTM
More Details of Recursion Pharmaceuticals Inc Company
Recursion Pharmaceuticals, Inc. is a clinical stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology include REC-617, REC-1245, REC-3565 and REC-4539. Its clinical programs in rare diseases include REC-994, REC-4881, REC-2282, and REC-3964. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors.
Company Info
Ticker SymbolRXRX
Company nameRecursion Pharmaceuticals Inc
IPO dateApr 16, 2021
Founded at2013
CEODr. Christopher Gibson, Ph.D.
Number of employees840
Security typeOrdinary Share
Fiscal year-endApr 16
Address41S Rio Grande Street
CitySALT LAKE CITY
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code84101
Phone13852690203
Websitehttps://www.recursion.com/
Ticker SymbolRXRX
IPO dateApr 16, 2021
Founded at2013
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.19M
+0.69%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
166.43K
-4.07%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
142.54K
-20.25%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
132.89K
+19.86%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
Dr. Najat Khan, Ph.D.
Dr. Najat Khan, Ph.D.
Director, Chief Research and Development Officer, Chief Commercial Officer
Director, Chief Research and Development Officer, Chief Commercial Officer
14.63K
-20.60%
Mr. Zachary Bogue, J.D.
Mr. Zachary Bogue, J.D.
Independent Director
Independent Director
9.38K
--
Dr. Franziska Michor, Ph.D.
Dr. Franziska Michor, Ph.D.
Independent Director
Independent Director
--
--
Dr. Blake Borgeson, Ph.D.
Dr. Blake Borgeson, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.19M
+0.69%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
166.43K
-4.07%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
142.54K
-20.25%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
132.89K
+19.86%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, May 28
Updated: Wed, May 28
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
8.71%
The Vanguard Group, Inc.
8.06%
Baillie Gifford & Co.
6.10%
BlackRock Institutional Trust Company, N.A.
5.02%
SB Global Advisers Ltd
3.67%
Other
68.43%
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
8.71%
The Vanguard Group, Inc.
8.06%
Baillie Gifford & Co.
6.10%
BlackRock Institutional Trust Company, N.A.
5.02%
SB Global Advisers Ltd
3.67%
Other
68.43%
Shareholder Types
Shareholders
Proportion
Investment Advisor
36.58%
Investment Advisor/Hedge Fund
19.62%
Venture Capital
8.74%
Sovereign Wealth Fund
4.12%
Individual Investor
3.17%
Research Firm
2.16%
Hedge Fund
2.01%
Corporation
1.93%
Bank and Trust
0.86%
Other
20.83%
Institutional Shareholding
Updated: Tue, Mar 4
Updated: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
637
324.02M
81.93%
+29.39M
2024Q4
611
317.29M
80.77%
+25.35M
2024Q3
560
281.65M
104.01%
-6.72M
2024Q2
527
272.94M
105.41%
+14.66M
2024Q1
478
234.97M
104.72%
-10.28M
2023Q4
433
227.80M
110.74%
+18.50M
2023Q3
402
195.18M
97.47%
+1.19M
2023Q2
358
172.49M
89.73%
-20.74M
2023Q1
345
171.25M
93.19%
-16.02M
2022Q4
321
167.85M
92.66%
-946.19K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARK Investment Management LLC
32.35M
8.19%
-422.79K
-1.29%
Dec 31, 2024
The Vanguard Group, Inc.
33.97M
8.6%
+9.74M
+40.18%
Dec 31, 2024
Baillie Gifford & Co.
24.86M
6.29%
-375.81K
-1.49%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
20.31M
5.14%
+2.56M
+14.39%
Dec 31, 2024
SB Global Advisers Ltd
14.67M
3.71%
+14.67M
--
Dec 31, 2024
Kinnevik AB
11.91M
3.01%
--
--
Dec 31, 2024
State Street Global Advisors (US)
12.58M
3.18%
-291.91K
-2.27%
Dec 31, 2024
Mubadala Investment Company PJSC
12.99M
3.29%
--
--
Dec 31, 2024
DCVC Management Co, LLC
5.94M
1.5%
-3.73M
-38.55%
Dec 31, 2024
Novo Holdings A/S
10.11M
2.56%
+10.11M
--
Dec 31, 2024
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
ARK Genomic Revolution ETF
4.95%
ARK Innovation ETF
1.5%
First Trust Nasdaq AI and Robotics ETF
1.01%
AXS Green Alpha ETF
0.81%
Franklin Genomic Advancements ETF
0.66%
WisdomTree BioRevolution Fund
0.64%
Main Thematic Innovation ETF
0.59%
SPDR S&P Biotech ETF
0.56%
Virtus LifeSci Biotech Clinical Trials ETF
0.45%
Direxion Daily S&P Biotech Bull 3X Shares
0.37%
View more
ARK Genomic Revolution ETF
Proportion4.95%
ARK Innovation ETF
Proportion1.5%
First Trust Nasdaq AI and Robotics ETF
Proportion1.01%
AXS Green Alpha ETF
Proportion0.81%
Franklin Genomic Advancements ETF
Proportion0.66%
WisdomTree BioRevolution Fund
Proportion0.64%
Main Thematic Innovation ETF
Proportion0.59%
SPDR S&P Biotech ETF
Proportion0.56%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.45%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.37%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
